INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2022

Oral nicotinamide and pyruvate significantly improved visual field test locations in patients with open-angle glaucoma.

In a phase 2 trial, 42 patients with treated open-angle glaucoma were randomized 2:1 to ascending doses of oral nicotinamide (1000-3000 mg) and pyruvate (1500-3000 mg) or placebo, with 32 completing the study. Over a median follow-up of 2.2 months, the number of improving visual field test locations was significantly higher in the intervention group than placebo (median [IQR], 15 [6-25] vs 7 [6-11]; P = .005). Rates of change in pattern standard deviation suggested improvement (median, -0.06 vs 0.02 dB/week; P = .02), whereas mean deviation (P = .35) and visual field index (P = .71) did not differ significantly. No serious adverse events were reported.

Study type
Phase 2 randomized, double-blind, placebo-controlled trial
Who was studied
32 completed participants with treated open-angle glaucoma and moderate visual field loss
What was measured
Visual field test locations improving beyond normal variability; rates of change of visual field global indices (MD, PSD, VFI)

THE PAPER

Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial.

De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. JAMA Ophthalmol, 2022.

PubMed 34792559 ↗DOI 10.1038/s41598-019-55345-x ↗

Nutrients & adequacyOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.